2009-2018年新药上市所需研发投资估算
该研究利用美国证券交易委员会、Drugs@FDA和ClinicalTrials.gov等公开数据,估算2009-2018年FDA批准的新治疗药物上市所需的研发支出。
要点
- 不同治疗领域差异明显,抗肿瘤和免疫调节剂中位投资最高。
- 仅18%的FDA批准产品有公开研发支出数据,结论需谨慎解读。
核心结论
- 与既往研究的差异可能反映分析产品范围、公开数据可及性及成本计算假设的不同。
研究设计与样本
- 研究分析了2009-2018年FDA批准的新治疗药物,数据来自美国证券交易委员会、Drugs@FDA数据库、ClinicalTrials.gov及已发表的临床试验成功率数据。
- FDA在 study 期间共批准355个新药和生物制品,其中63个(18%)产品有研发支出数据,由47家公司开发。
关键数值与推荐
- 资本化采用年实际资本成本率10.5%,所有金额以2018年美元报告,置信区间通过bootstrapping方法获得。
临床怎么用
- 该估算可为研发投资决策、政策讨论和药物定价分析提供参考,但需注意数据主要来自小型公司、孤儿药、特定治疗领域、首创药物、加速审批产品及2014-2018年批准的产品。
局限性
- 研发支出数据仅覆盖18%的批准产品,且主要可及于小型公司、孤儿药、特定领域、首创药物、加速审批产品及2014-2018年批准的产品。
- 敏感性分析中,采用不同的临床试验成功率、临床前支出和资本成本估计时结果会变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The mean cost of developing a new drug has been the subject of debate, with recent estimates ranging from $314 million to $2.8 billion. OBJECTIVE: To estimate the research and development investment required to bring a new therapeutic agent to market, using publicly available data. DESIGN AND SETTING: Data were analyzed on new therapeutic agents approved by the US Food and Drug Administration (FDA) between 2009 and 2018 to estimate the research and development expenditure required to bring a new medicine to market. Data were accessed from the US Securities and Exchange Commission, Drugs@FDA database, and ClinicalTrials.gov, alongside published data on clinical trial success rates. EXPOSURES: Conduct of preclinical and clinical studies of new therapeutic agents. MAIN OUTCOMES AND MEASURES: Median and mean research and development spending on new therapeutic agents approved by the FDA, capitalized at a real cost of capital rate (the required rate of return for an investor) of 10.5% per year, with bootstrapped CIs. All amounts were reported in 2018 US dollars. RESULTS: The FDA approved 355 new drugs and biologics over the study period. Research and development expenditures were available for 63 (18%) products, developed by 47 different companies. After accounting for the costs of failed trials, the median capitalized research and development investment to bring a new drug to market was estimated at $985.3 million (95% CI, $683.6 million-$1228.9 million), and the mean investment was estimated at $1335.9 million (95% CI, $1042.5 million-$1637.5 million) in the base case analysis. Median estimates by therapeutic area (for areas with ≥5 drugs) ranged from $765.9 million (95% CI, $323.0 million-$1473.5 million) for nervous system agents to $2771.6 million (95% CI, $2051.8 million-$5366.2 million) for antineoplastic and immunomodulating agents. Data were mainly accessible for smaller firms, orphan drugs, products in certain therapeutic areas, first-in-class drugs, therapeutic agents that received accelerated approval, and products approved between 2014 and 2018. Results varied in sensitivity analyses using different estimates of clinical trial success rates, preclinical expenditures, and cost of capital. CONCLUSIONS AND RELEVANCE: This study provides an estimate of research and development costs for new therapeutic agents based on publicly available data. Differences from previous studies may reflect the spectrum of products analyzed, the restricted availability of data in the public domain, and differences in underlying assumptions in the cost calculations.
引用
- Wouters OJ, McKee M, Luyten J, et al. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020. PMID: 32125404. doi:10.1001/jama.2020.1166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。